vs
BayCom Corp（BCML）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是BayCom Corp的1.4倍（$35.5M vs $25.9M），BayCom Corp净利率更高（26.5% vs -304.2%，领先330.7%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 9.4%），BayCom Corp自由现金流更多（$30.1M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 2.9%）
BayCom Corp是总部位于美国的银行控股公司，旗下拥有海湾商业银行，主要服务北加州地区的中小微企业与零售客户，提供商业贷款、存款产品、个人银行、财富管理等多元金融服务，深耕本土社区金融市场。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
BCML vs RXRX — 直观对比
营收规模更大
RXRX
是对方的1.4倍
$25.9M
营收增速更快
RXRX
高出672.3%
9.4%
净利率更高
BCML
高出330.7%
-304.2%
自由现金流更多
BCML
多$77.4M
$-47.3M
两年增速更快
RXRX
近两年复合增速
2.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $25.9M | $35.5M |
| 净利润 | $6.9M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 36.6% | -304.8% |
| 净利率 | 26.5% | -304.2% |
| 营收同比 | 9.4% | 681.7% |
| 净利润同比 | 12.1% | 39.6% |
| 每股收益（稀释后） | $0.63 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCMLRXRX
| Q4 25 | $25.9M | $35.5M | ||
| Q3 25 | $25.7M | $5.2M | ||
| Q2 25 | $24.7M | $19.2M | ||
| Q1 25 | $24.3M | $14.7M | ||
| Q4 24 | $23.7M | $4.5M | ||
| Q3 24 | $25.6M | $26.1M | ||
| Q2 24 | $23.8M | $14.4M | ||
| Q1 24 | $24.5M | $13.8M |
净利润BCMLRXRX
| Q4 25 | $6.9M | $-108.1M | ||
| Q3 25 | $5.0M | $-162.3M | ||
| Q2 25 | $6.4M | $-171.9M | ||
| Q1 25 | $5.7M | $-202.5M | ||
| Q4 24 | $6.1M | $-178.9M | ||
| Q3 24 | $6.0M | $-95.8M | ||
| Q2 24 | $5.6M | $-97.5M | ||
| Q1 24 | $5.9M | $-91.4M |
毛利率BCMLRXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率BCMLRXRX
| Q4 25 | 36.6% | -304.8% | ||
| Q3 25 | 26.3% | -3327.6% | ||
| Q2 25 | 35.3% | -916.8% | ||
| Q1 25 | 31.6% | -1297.9% | ||
| Q4 24 | 34.2% | -4042.4% | ||
| Q3 24 | 32.4% | -377.1% | ||
| Q2 24 | 31.9% | -697.4% | ||
| Q1 24 | 33.3% | -698.4% |
净利率BCMLRXRX
| Q4 25 | 26.5% | -304.2% | ||
| Q3 25 | 19.5% | -3135.3% | ||
| Q2 25 | 25.8% | -894.2% | ||
| Q1 25 | 23.4% | -1373.3% | ||
| Q4 24 | 25.9% | -3935.5% | ||
| Q3 24 | 23.5% | -367.5% | ||
| Q2 24 | 23.6% | -676.6% | ||
| Q1 24 | 24.0% | -662.4% |
每股收益（稀释后）BCMLRXRX
| Q4 25 | $0.63 | $-0.17 | ||
| Q3 25 | $0.46 | $-0.36 | ||
| Q2 25 | $0.58 | $-0.41 | ||
| Q1 25 | $0.51 | $-0.50 | ||
| Q4 24 | $0.55 | $-0.56 | ||
| Q3 24 | $0.54 | $-0.34 | ||
| Q2 24 | $0.50 | $-0.40 | ||
| Q1 24 | $0.51 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $338.6M | $1.1B |
| 总资产 | $2.6B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资BCMLRXRX
| Q4 25 | — | $743.3M | ||
| Q3 25 | — | $659.8M | ||
| Q2 25 | — | $525.1M | ||
| Q1 25 | — | $500.5M | ||
| Q4 24 | — | $594.4M | ||
| Q3 24 | — | $427.6M | ||
| Q2 24 | — | $474.3M | ||
| Q1 24 | — | $296.3M |
总债务BCMLRXRX
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益BCMLRXRX
| Q4 25 | $338.6M | $1.1B | ||
| Q3 25 | $334.3M | $1.0B | ||
| Q2 25 | $330.6M | $919.1M | ||
| Q1 25 | $329.3M | $933.9M | ||
| Q4 24 | $324.4M | $1.0B | ||
| Q3 24 | $321.7M | $524.6M | ||
| Q2 24 | $315.3M | $584.4M | ||
| Q1 24 | $314.2M | $401.2M |
总资产BCMLRXRX
| Q4 25 | $2.6B | $1.5B | ||
| Q3 25 | $2.6B | $1.4B | ||
| Q2 25 | $2.6B | $1.3B | ||
| Q1 25 | $2.6B | $1.3B | ||
| Q4 24 | $2.7B | $1.4B | ||
| Q3 24 | $2.6B | $726.5M | ||
| Q2 24 | $2.6B | $775.9M | ||
| Q1 24 | $2.6B | $557.8M |
负债/权益比BCMLRXRX
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $31.8M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $30.1M | $-47.3M |
| 自由现金流率自由现金流/营收 | 116.2% | -133.1% |
| 资本支出强度资本支出/营收 | 6.7% | 3.5% |
| 现金转化率经营现金流/净利润 | 4.64× | — |
| 过去12个月自由现金流最近4个季度 | $51.1M | $-378.3M |
8季度趋势，按日历期对齐
经营现金流BCMLRXRX
| Q4 25 | $31.8M | $-46.1M | ||
| Q3 25 | $7.3M | $-117.4M | ||
| Q2 25 | $6.4M | $-76.4M | ||
| Q1 25 | $9.3M | $-132.0M | ||
| Q4 24 | $30.4M | $-115.4M | ||
| Q3 24 | $9.6M | $-59.2M | ||
| Q2 24 | $7.7M | $-82.2M | ||
| Q1 24 | $5.1M | $-102.3M |
自由现金流BCMLRXRX
| Q4 25 | $30.1M | $-47.3M | ||
| Q3 25 | $6.2M | $-117.6M | ||
| Q2 25 | $5.6M | $-79.6M | ||
| Q1 25 | $9.1M | $-133.8M | ||
| Q4 24 | $28.7M | $-116.7M | ||
| Q3 24 | $9.4M | $-63.8M | ||
| Q2 24 | $7.4M | $-83.4M | ||
| Q1 24 | $3.9M | $-109.0M |
自由现金流率BCMLRXRX
| Q4 25 | 116.2% | -133.1% | ||
| Q3 25 | 24.3% | -2272.5% | ||
| Q2 25 | 22.8% | -413.9% | ||
| Q1 25 | 37.6% | -907.4% | ||
| Q4 24 | 121.1% | -2567.7% | ||
| Q3 24 | 36.6% | -244.6% | ||
| Q2 24 | 31.2% | -578.5% | ||
| Q1 24 | 16.1% | -789.9% |
资本支出强度BCMLRXRX
| Q4 25 | 6.7% | 3.5% | ||
| Q3 25 | 4.3% | 4.7% | ||
| Q2 25 | 3.0% | 16.4% | ||
| Q1 25 | 0.6% | 12.4% | ||
| Q4 24 | 7.2% | 28.6% | ||
| Q3 24 | 1.0% | 17.5% | ||
| Q2 24 | 1.0% | 8.2% | ||
| Q1 24 | 4.7% | 48.2% |
现金转化率BCMLRXRX
| Q4 25 | 4.64× | — | ||
| Q3 25 | 1.47× | — | ||
| Q2 25 | 1.00× | — | ||
| Q1 25 | 1.63× | — | ||
| Q4 24 | 4.96× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.37× | — | ||
| Q1 24 | 0.86× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
